Drugs / Milnacipran
Milnacipran
also known as
Savella · Dalcipran · Impulsor · Ixel · Ixel (outside of United States) · Milnacipram · Milnacipran hcl · Milnacipran hydrochloride · +5 more
Other / unclassified targets SLC6A2, SLC6A4 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Refused (EMA) | EU (EMA) | Milnacipran Pierre Fabre Medicament | — | 2010-04-08 | europa.eu ↗ |
| Approved | US (FDA) | SAVELLA | — | 2009-01-14 | fda.gov ↗ |
Trials 34 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 24 trials | ||||||
| Phase 2 | NCT01328002 | Apr 2011 → Aug 2012 | fibromyalgia | Forest Laboratories | Terminated | No outcome recorded |
| Phase 2 | NCT01331109 | Apr 2011 → Aug 2012 | fibromyalgia | Forest Laboratories | Terminated | No outcome recorded |
| Phase 2 | NCT01225068 | Oct 2010 → Jan 2012 | — | Northwestern University | Completed | No outcome recorded |
| Phase 2 | NCT00757679 | Sep 2006 → Sep 2009 | fibromyalgia | Pierre Fabre Laboratories | Completed | No outcome recorded |
| Phase 313 trials | ||||||
| Phase 3 | NCT01829243 | Jul 2011 → May 2013 | cognitive disorder, fibromyalgia | Duke University | Completed | No outcome recorded |
| Phase 3 | NCT01288937 | Apr 2011 → Oct 2014 | peripheral neuropathy | Columbia University | Terminated | No outcome recorded |
| Phase 3 | NCT01418651 | Mar → Aug 2011 | fibromyalgia | Banner Health | Terminated | No outcome recorded |
| Phase 3 | NCT01304589 | Oct 2010 → Sep 2012 | vulvodynia | University of Tennessee | Completed | No outcome recorded |
| Phase 3 | NCT01221740 | Aug 2010 → Aug 2011 | — | Brigham and Women's Hospital | Withdrawn | No outcome recorded |
| Phase 3 | NCT00793520 | Nov 2008 → Apr 2009 | fibromyalgia | Forest Laboratories | Terminated | No outcome recorded |
| Phase 3 | NCT00797797 | Nov 2008 → Nov 2009 | fibromyalgia | Forest Laboratories | Completed | No outcome recorded |
| Phase 3 | NCT00618956 | Oct 2007 → Jul 2008 | fibromyalgia | Forest Laboratories | Completed | No outcome recorded |
| Phase 3 | NCT00757731 | Sep 2006 → Oct 2008 | fibromyalgia | Pierre Fabre Laboratories | Completed | No outcome recorded |
| Phase 3 | NCT00314249 | Apr 2006 → Jun 2008 | fibromyalgia | Forest Laboratories | Completed | No outcome recorded |
| Phase 3 | NCT00436033 | Feb 2006 → Sep 2007 | fibromyalgia | Pierre Fabre Laboratories | Completed | No outcome recorded |
| Phase 3 | NCT00098124 | Nov 2004 → Dec 2006 | fibromyalgia | Forest Laboratories | Completed | No outcome recorded |
| Phase 3 | NCT00225511 | Jun 2004 → ? | depressive disorder | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 414 trials | ||||||
| Phase 4 | NCT01359826 | Oct 2011 → Jun 2013 | fibromyalgia, systemic lupus erythematosus | Loma Linda University | Withdrawn | No outcome recorded |
| Phase 4 | NCT01329406 | Jul 2011 → Feb 2012 | osteoarthritis | Analgesic Solutions | Unknown | No outcome recorded |
| Phase 4 | NCT01319825 | Apr 2011 → May 2012 | migraine with aura, migraine without aura | California Medical Clinic for Headache | Unknown | No outcome recorded |
| Phase 4 | NCT01288807 | Feb 2011 → Jan 2015 | fibromyalgia | University of California, San Diego | Completed | No outcome recorded |
| Phase 4 | NCT01337700 | Feb 2011 → Jul 2014 | autism spectrum disorder | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01207453 | Jan 2011 → Nov 2013 | rheumatoid arthritis | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01234675 | Nov 2010 → Feb 2014 | fibromyalgia, sleep disorder | Mansoor Ahmed M.D. | Completed | No outcome recorded |
| Phase 4 | NCT01225991 | Nov 2010 → May 2013 | rheumatoid arthritis | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 4 | NCT01510457 | Nov 2010 → Oct 2013 | chronic pain syndrome, osteoarthritis, knee | Dr. Norman Harden | Completed | No outcome recorded |
| Phase 4 | NCT01780389 | Oct 2010 → Jul 2011 | osteoarthritis | Duke University | Completed | No outcome recorded |
| Phase 4 | NCT01173055 | Jun 2010 → Jun 2012 | fibromyalgia | University of Michigan | Completed | No outcome recorded |
| Phase 4 | NCT01777581 | Mar 2010 → Oct 2011 | lumbar disk disease | Duke University | Completed | No outcome recorded |
| Phase 4 | NCT01077375 | Feb → Dec 2010 | fibromyalgia | Forest Laboratories | Completed | No outcome recorded |
| Phase 4 | NCT01014585 | Nov 2009 → May 2010 | fibromyalgia | Forest Laboratories | Completed | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT00606203 | Sep 2007 → Sep 2010 | depressive disorder, ischemic stroke | Chang Gung Memorial Hospital | Unknown | No outcome recorded |
| — | NCT01352572 | Jan 2002 → Dec 2018 | depressive disorder | Samsung Medical Center | Unknown | No outcome recorded |
| — | NCT01352559 | Nov 2001 → Mar 2007 | depressive disorder | Samsung Medical Center | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 18 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01294059 Comparator | Nov 2009 → Apr 2014 | fibromyalgia | University of Florida | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT03321526 Background | Dec 2017 → Jun 2019 | major depressive disorder | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT01914042 Comparator | Jul 2013 → Jul 2019 | neuropathy, painful | Rambam Health Care Campus | Unknown | No outcome recorded |
| Phase 2 | NCT01747044 Comparator | Apr 2013 → Nov 2014 | fibromyalgia | University Hospital, Clermont-Ferrand | Unknown | No outcome recorded |
| Phase 2 | NCT01471379 Comparator | Apr 2012 → Feb 2013 | irritable bowel syndrome | Spencer Dorn, MD, MPH | Terminated | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT02783430 Background | Sep 2016 → Mar 2024 | depressive disorder | University Hospital, Lille | Completed | No outcome recorded |
| Phase 2/3 | NCT01108731 Comparator | Mar 2010 → Jan 2014 | fibromyalgia | Beth Israel Medical Center | Completed | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT01125423 Comparator | May 2010 → Jan 2013 | fibromyalgia | Albany Medical College | Completed | No outcome recorded |
| Phase 4 | NCT01038323 Comparator | Dec 2009 → Sep 2012 | fibromyalgia | Indiana University | Completed | No outcome recorded |
| Phase 4 | NCT01289236 Comparator | Oct 2009 → Jun 2011 | chronic pain syndrome | Valera Bussell | Completed | No outcome recorded |
| Phase not applicable8 trials | ||||||
| — | NCT07533487 Background | Sep 2022 → Jan 2025 | fibromyalgia | Cairo University | Completed | No outcome recorded |
| — | NCT05384210 Comparator | Jun 2022 → Oct 2023 | fibromyalgia | Mansoura University | Unknown | No outcome recorded |
| — | NCT03905486 Comparator | Apr → Nov 2019 | fibromyalgia | Yousra Hisham Abdel Fattah | Completed | No outcome recorded |
| — | NCT02687165 Comparator | Jan 2016 → Jan 2017 | chronic pain syndrome, post-treatment Lyme disease syndrome | New York State Psychiatric Institute | Terminated | No outcome recorded |
| — | NCT01488266 Comparator | Nov 2011 → Jan 2013 | major depressive disorder | Korea University | Unknown | No outcome recorded |
| — | NCT01393522 Comparator | Jun 2011 → Dec 2013 | migraine disorder | Timothy Smith | Completed | No outcome recorded |
| — | NCT01228357 Comparator | Feb 2003 → Dec 2018 | depressive disorder | Samsung Medical Center | Unknown | No outcome recorded |
| — | NCT00817375 Comparator | Feb 2003 → Dec 2018 | depressive disorder | Samsung Medical Center | Unknown | No outcome recorded |
Evidence & citations 19 cited values
Every value below carries the sentence it was read from. 54 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | milnacipran | “Aim of the work: To compare the efficacy of pregabalin agent (averopreg) alone versus combined pregabalin and serotonin norepinephrine reuptake inhibitor (milnacipran) in the...” NCT03905486 ↗48“Participants will receive SNRI antidepressant (such as duloxetine, milnacipran, levomilnacipran, venlafaxine, desvenlafaxine) as a part of background therapy” NCT03321526 ↗ “non-SSRI treated group is depressive patients treated with milnacipran, venlafaxine, nortriptyline, or mirtazapine” NCT00817375 ↗ “pain relievers such as acetaminophen and antidepressants such as Duloxetine (Cymbalta) and milnacipran” NCT07533487 ↗ “milnacipran” NCT01488266 ↗ “milnacipran” NCT01228357 ↗ “milnacipran” NCT01352559 ↗ “milnacipran” NCT01352572 ↗ |
| Known as | Dalcipran | ChEMBL registry synonym — accepted as the source's own label CHEMBL259209 ↗ |
| Known as | Impulsor | ChEMBL registry synonym — accepted as the source's own label CHEMBL259209 ↗ |
| Known as | Ixel | “Milnacipran (Ixel)- a serotonin-norepinephrine reuptake inhibitor (SNRI)” NCT01914042 ↗ |
| Known as | Ixel (outside of United States) | “Ixel (outside of United States)” NCT00618956 ↗ |
| Known as | Milnacipram | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01288807 ↗ |
| Known as | Milnacipran hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL259209 ↗ |
| Known as | Milnacipran hydrochloride | “Drug: Milnacipran hydrochloride” NCT00618956 ↗ |
| Known as | Milnacipran pierre fabre medicament | ChEMBL registry synonym — accepted as the source's own label CHEMBL259209 ↗ |
| Known as | MLN | “Gabapentin and milnacipran (MLN) show strong evidence of reduced pain, increased sleep, and improvement in the quality of life in fibromyalgia (FM) patients.” NCT05384210 ↗ |
| Known as | NSC-759806 | ChEMBL registry synonym — accepted as the source's own label CHEMBL259209 ↗ |
| Known as | Savella | “This medicine is known as Milnacipran (the trade name is "Savella"); this medicine is not addictive and it has been shown to reduce chronic pain by its multiple actions on pain...” NCT02687165 ↗4“Savella ®, (milnacipran) is an FDA approved drug for fibromyalgia.” NCT01038323 ↗ “Savella” NCT01393522 ↗ |
| Known as | Savella (milnacipran HCL) Tablets | “Savella (milnacipran HCL) Tablets” NCT01510457 ↗ |
| Known as | Toledomin | ChEMBL registry synonym — accepted as the source's own label CHEMBL259209 ↗ |
| Action | Inhibit | “milnacipran, a dual norepinephrine-serotonin reuptake inhibitor” PMID 19108787 ↗ Nov 20082“Norepinephrine transporter inhibitor” CHEMBL259209 ↗ “Serotonin transporter inhibitor” CHEMBL259209 ↗ |
| Modality | Other / unclassified | “serotonin-norepinephrine reuptake inhibitor (SNRI)” NCT01329406 ↗ |
| Route | Oral | “oral administration” NCT00618956 ↗ |
| Target | SLC6A2 | “Norepinephrine transporter inhibitor” CHEMBL259209 ↗ |
| Target | SLC6A4 | “Serotonin transporter inhibitor” CHEMBL259209 ↗ |